

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

RECEIVED
SECRETARY OF THE SENATE
PUBLIC RECORDS

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name				
Organization		Boehringer Ingelheim Pharmaceuticals, Inc.		
2. Address <input type="checkbox"/> Check if different than previously reported				
Address1 1201 Pennsylvania Ave., N.W., Suite 315				
City Washington		State DC	Zip Code 20004	Country USA
3. Principal place of business (if different than line 2)				
City		State	Zip Code	Country
City		State/Zip or Country		
4a. Contact Name		b. Telephone number		c. E-mail
Prefix	Full Name			
Mr.	Henry W. Menn III	202-347-8270		mnoonan@rdg.boehringer-ingelheim.com
7. Client Name <input checked="" type="checkbox"/> Self				5. Senate ID #
Boehringer Ingelheim Pharmaceuticals, Inc.				292972-12
				6. House ID #
				37344000

TYPE OF REPORT 8. Year 2006 Midyear (January 1-June 30) ☒ OR Year End (July 1-December 3)

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ ⇔ Termination Date _____ 11. No Lobbying Activi

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇔ \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇔ \$ <u>855,000</u></p> <p>14. REPORTING METHOD. Check box to indicate expen: accounting method. See instructions for description of optio</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) o Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Revenue Code</p>
---	---

Form Co

Printed Name and Title Kristen D. W. Morris VP, Government Affairs & Public Policy

Registrant Name **Boehringer Ingelheim Pharmaceuticals, Inc.**

Client Name **Boehringer Ingelheim Pharmaceuticals, Inc**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide the information as requested. Attach additional page(s) as needed.

15. General issue area code MMM - Medicare/Medicaid (one per page)

16. Specific lobbying issues

S.3650, Helping Fill the Medicare Rx GAP Act of 2006
Issues pertaining to the Medicare Part D Drug Benefit Implementation

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

House
Senate

18. Name of each individual who acted as a lobbyist in this issue area

[illegible]

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title Kristen D. W. Morris VP, Government Affairs & Public Policy

LD-2DS (Rev. 4.06)

Filing #6ccb6d18-07b9-4ef3-a57c-593cb7478cd6 - Page 3 of 20

1000201246

mean Jew

YVACKU NW

Registrant Name Boehringer Ingelheim Pharmaceuticals, Inc. Client Name Boehringer Ingelheim Pharmaceuticals, Inc.

gmsiruvom

15. General issue area code ANI - Animals (one per page)

HR. 4239, Animal Enterprise Terrorism Act
S. 1926, Animal Enterprise Terrorism Act

House
Senate[illegible]

0000201249

Printed Name and Title **Kristen D. W. Morris VP, Government Affairs & Public Policy**

Handwritten signature

Registrant Name Boehringer Ingelheim Pharmaceuticals, Inc. Client Name Boehringer Ingelheim Pharmaceuticals, Inc.

MSU DUTCH

Registrant Name Boehringer Ingelheim Pharmaceuticals, Inc.Client Name Boehringer Ingelheim Pharmaceuticals, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code HCR - Health Issues (one per page)

16. Specific lobbying issues

Issues relating to CFC supply and essentiality
 HR. 328, Pharmaceutical Market Access Act of 2005
 S. 109, Pharmaceutical Market Access Act of 2005
 S. 2339, Ryan White CARE Act Amendments of 2006
 HR. 5009, Ryan White CARE Act Amendments of 2006
 Issues pertaining to pharmaceutical compounding

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

House
 Senate
 U.S. Food and Drug Administration
 U.S. Department of State
 U.S. Environmental Protection Agency

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Kristen D. W.	Morris		
Henry W.	Menn III		

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title Kristen D. W. Morris VP, Government Affairs & Public Policy

9mL2UW0m

Registrant Name Boehringer Ingelheim Pharmaceuticals, Inc. Client Name Boehringer Ingelheim Pharmaceuticals, Inc.

Registrant Name Boehringer Ingelheim Pharmaceuticals, Inc. Client Name Boehringer Ingelheim Pharmaceuticals, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide the information as requested. Attach additional page(s) as needed.

15. General issue area code BUD - Budget/Appropriations (one per page)

16. Specific lobbying issues

HR. 4241, Deficit Reduction Act of 2005
S. 1932, Deficit Reduction Omnibus Reconciliation Act of 2005
S. CON. RES. 83, Congressional Budget for Government for FY 2007
H. CON. RES. 373, Congressional Budget for U.S. Government for FY 2007
HR.5441, Making Appropriations for the Department of Homeland Security for FY 2007

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

	House	Senate
1. <i>Legislation</i>	100	100
2. <i>Executive Orders</i>	100	100
3. <i>Administrative Actions</i>	100	100
4. <i>Regulations</i>	100	100
5. <i>Committee Reports</i>	100	100
6. <i>Public Laws</i>	100	100
7. <i>Joint Resolutions</i>	100	100
8. <i>Constitutional Amendments</i>	100	100
9. <i>Executive Agreements</i>	100	100
10. <i>Administrative Decisions</i>	100	100
11. <i>Regulatory Actions</i>	100	100
12. <i>Committee Hearings</i>	100	100
13. <i>Public Bills</i>	100	100
14. <i>Joint Resolutions</i>	100	100
15. <i>Constitutional Amendments</i>	100	100
16. <i>Executive Orders</i>	100	100
17. <i>Administrative Actions</i>	100	100
18. <i>Regulations</i>	100	100
19. <i>Committee Reports</i>	100	100
20. <i>Public Laws</i>	100	100
21. <i>Joint Resolutions</i>	100	100
22. <i>Constitutional Amendments</i>	100	100
23. <i>Executive Agreements</i>	100	100
24. <i>Administrative Decisions</i>	100	100
25. <i>Regulatory Actions</i>	100	100
26. <i>Committee Hearings</i>	100	100
27. <i>Public Bills</i>	100	100
28. <i>Joint Resolutions</i>	100	100
29. <i>Constitutional Amendments</i>	100	100
30. <i>Executive Orders</i>	100	100
31. <i>Administrative Actions</i>	100	100
32. <i>Regulations</i>	100	100
33. <i>Committee Reports</i>	100	100
34. <i>Public Laws</i>	100	100
35. <i>Joint Resolutions</i>	100	100
36. <i>Constitutional Amendments</i>	100	100
37. <i>Executive Agreements</i>	100	100
38. <i>Administrative Decisions</i>	100	100
39. <i>Regulatory Actions</i>	100	100
40. <i>Committee Hearings</i>	100	100
41. <i>Public Bills</i>	100	100
42. <i>Joint Resolutions</i>	100	100
43. <i>Constitutional Amendments</i>	100	100
44. <i>Executive Orders</i>	100	100
45. <i>Administrative Actions</i>	100	100
46. <i>Regulations</i>	100	100
47. <i>Committee Reports</i>	100	100
48. <i>Public Laws</i>	100	100
49. <i>Joint Resolutions</i>	100	100
50. <i>Constitutional Amendments</i>	100	100
51. <i>Executive Agreements</i>	100	100
52. <i>Administrative Decisions</i>	100	100
53. <i>Regulatory Actions</i>	100	100
54. <i>Committee Hearings</i>	100	100
55. <i>Public Bills</i>	100	100
56. <i>Joint Resolutions</i>	100	100
57. <i>Constitutional Amendments</i>	100	100
58. <i>Executive Orders</i>	100	100
59. <i>Administrative Actions</i>	100	100
60. <i>Regulations</i>	100	100
61. <i>Committee Reports</i>	100	100
62. <i>Public Laws</i>	100	100
63. <i>Joint Resolutions</i>	100	100
64. <i>Constitutional Amendments</i>	100	100
65. <i>Executive Agreements</i>	100	100
66. <i>Administrative Decisions</i>	100	100
67. <i>Regulatory Actions</i>	100	100
68. <i>Committee Hearings</i>	100	100
69. <i>Public Bills</i>	100	100
70. <i>Joint Resolutions</i>	100	100
71. <i>Constitutional Amendments</i>	100	100
72. <i>Executive Orders</i>	100	100
73. <i>Administrative Actions</i>	100	100
74. <i>Regulations</i>	100	100
75. <i>Committee Reports</i>	100	100
76. <i>Public Laws</i>	100	100
77. <i>Joint Resolutions</i>	100	100
78. <i>Constitutional Amendments</i>	100	100
79. <i>Executive Agreements</i>	100	100
80. <i>Administrative Decisions</i>	100	100
81. <i>Regulatory Actions</i>	100	100
82. <i>Committee Hearings</i>	100	100
83. <i>Public Bills</i>	100	100
84. <i>Joint Resolutions</i>	100	100
85. <i>Constitutional Amendments</i>	100	100
86. <i>Executive Orders</i>	100	100
87. <i>Administrative Actions</i>	100	100
88. <i>Regulations</i>	100	100
89. <i>Committee Reports</i>	100	100
90. <i>Public Laws</i>	100	100
91. <i>Joint Resolutions</i>	100	100
92. <i>Constitutional Amendments</i>	100	100
93. <i>Executive Agreements</i>	100	100
94. <i>Administrative Decisions</i>	100	100
95. <i>Regulatory Actions</i>	100	100
96. <i>Committee Hearings</i>	100	100
97. <i>Public Bills</i>	100	10

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this*

[illegible]

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Add a page for a differer

Printed Name and Title Kristen D. W. Morris VP, Government Affairs & Public Policy

0000201252

Handwritten signature

Registrant Name Boehringer Ingelheim Pharmaceuticals, Inc.Client Name Boehringer Ingelheim Pharmaceuticals, Inc.**ADDENDUM for General Lobbying Issue Area BUD**

16. Specific lobbying issues (continued from previous page)

HR. 5384, Making Appropriations for Agriculture, Rural Development, Food and Drug Administration and Related Agencies for FY2007

HR. 5647 Making Appropriations for the Departments of Labor, Health and Human Services and Education for FY 2007

S. 3708, Making Appropriations for the Departments of Labor, Health and Human Services and Education for 2007

Add page to continue specific issues description for this is



Registrant Name Boehringer Ingelheim Pharmaceuticals, Inc. Client Name Boehringer Ingelheim Pharmaceuticals, Inc

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address

City

State

Zip Code

Country

21. Client new principal place of business (if different than line 20)

City

State

Zip Code

Country

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

First Name

Last Name

Suffix

First Name

Last Name

Suffi

1

3

2

4

ISSUE UPDATE

Find the code to select below.

24. General lobbying issues that **no longer** pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal place of Business (city and state or country)
	Address	City
	C/S/Z	State Country
	Address	City
	C/S/Z	State

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

1

2

3

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Own perce client
	Street Address			
	City State/Province Country	City		
		State Country		

28. Name of each previously reported foreign entity that **no longer** owns, **or** controls, **or** is affiliated with the registrant, cl
affiliated organization

1

3

5

2

4

6

Add a page for more up

Printed Name and Title Kristen D. W. Morris VP, Government Affairs & Public Policy

[Handwritten signature]